Overview
The Maestro system from Moon Surgical takes a fundamentally different approach to surgical robotics: rather than replacing the surgeon's hands with robot arms, Maestro acts as an intelligent robotic camera and instrument holder that collaborates alongside the surgeon during laparoscopic procedures.
Using two robotic arms that mount to the OR table, Maestro can hold and precisely reposition a laparoscopic camera and a second instrument autonomously — responding to the surgeon's commands via foot pedal, head tracking, or voice control. This frees both of the surgeon's hands to operate instruments, effectively giving solo surgeons the capability that normally requires a skilled assistant or scrub tech to maintain.
FDA-cleared in 2023, Maestro is the first collaborative surgical robot to reach the US market — occupying a completely different competitive space from full robotic surgery systems like da Vinci and Hugo.
Key Technology
🤝
Collaborative Architecture
Designed to assist — not replace — the surgeon. Both hands remain free for instrument control while Maestro manages camera positioning and one ancillary instrument.
🦶
Multi-Modal Control
Surgeon controls Maestro arms via foot pedal, head-tracking camera direction, or voice commands — keeping workflow natural without breaking sterile field.
🔌
Table-Mounted, Low Footprint
Mounts directly to the operating table rail — no large OR cart, no special OR room configuration. Deploys in minutes alongside any laparoscopic tower setup.
🔧
Instrument-Agnostic
Works with standard 5mm and 10mm laparoscopic instruments from any manufacturer. No proprietary instrument lock-in — unlike traditional robotic surgery platforms.
Strategic Position
Market Gap
Addresses the 80% of Laparoscopic Cases Not Roboticized
Full robotic surgery systems (da Vinci, Hugo) are adopted in major academic centers but remain cost-prohibitive for community and rural hospitals. Maestro brings robotic-level precision to standard laparoscopic environments at a fraction of the cost.
Cost Model
Subscription vs. Capital Purchase
Moon Surgical offers Maestro on a subscription model, dramatically lowering the barrier to adoption vs. $1–2M+ capital purchases required for full robotic surgery systems.
Surgeon Benefit
Eliminates Camera-Holder Dependency
Studies show camera holder fatigue and suboptimal camera positioning are significant factors in laparoscopic surgical errors. Maestro eliminates this variable entirely.
Timeline
2019
Moon Surgical founded in Paris; collaborative robotics concept development
2021
CE Mark approval; first European commercial cases completed
2022
Series B funding closed; US regulatory pathway initiated
2023
FDA 510(k) clearance; US commercial launch; subscription model introduced
2025
Growing US hospital adoption; expanding indications to additional laparoscopic procedures